To amend title XVIII of the Social Security Act to ensure equitable payment for, and preserve Medicare beneficiary access to, cancer treatments under the Medicare hospital outpatient prospective payment system.
Summary
HR8032 (FAIC Act) is an early-stage bill requiring separate Medicare Part B payment for qualifying cancer drugs, eliminating a hospital incentive to avoid expensive branded oncology therapies. The bill protects $50B+ in oncology drug revenue for major pharma companies but faces a long legislative path through two committees. Current stock prices for affected tickers are near the bottom of their 52-week ranges, suggesting market pessimism is already priced in, creating asymmetric upside if the bill advances.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR8032 (FAIC Act) mandates separate Medicare Part B payment for qualifying cancer drugs, removing the hospital incentive to avoid administering expensive branded therapies in exchange for fixed bundled payments.
- 2.The bill directly protects an estimated $50B+ in annual oncology drug revenue at MRK, BMY, PFE, LLY, AMGN, and JNJ — all of which trade near the bottom of their 52-week ranges after a 30-day selloff.
- 3.At early stage (referred to committee, 3 cosponsors), passage probability is low, but the bill represents the strongest legislative signal in this Congress toward protecting pharma oncology margins from hospital payment reform.
Market Implications
The six major oncology-exposed tickers (MRK, BMY, PFE, LLY, AMGN, JNJ) are all trading at depressed levels relative to their 52-week highs, with an average 30-day decline of 3.75%. MRK (-8.09% in 30 days to $110.56) and JNJ (-6.3% to $229.05) show the most severe recent weakness. The FAIC Act provides a named, specific legislative catalyst for a structural reversal of these trends — if the bill gains traction. However, at the current early stage with only 4 total actions and referral to two committees, near-term market impact is minimal. The real opportunity is monitoring committee markups: if either Energy & Commerce or Ways and Means schedules a hearing or markup, that event would validate the bill's momentum and trigger a revaluation of oncology pharma stocks that have been priced for continued pricing pressure. For active traders, the asymmetric risk/reward favors long positions in MRK and JNJ as the most depressed names with the most direct Keytruda/Darzalex exposure. For long-term holders, the bill reinforces the thesis that Congress will protect high-cost cancer drug margins in the Medicare outpatient setting.
Full Analysis
On March 20, 2026, Representative Dunn (R-FL) introduced HR8032, the Facilitating Access to Innovation in Cancer Care Act (FAIC Act). The bill is in the earliest legislative stage — referred to both the Committee on Energy and Commerce and the Committee on Ways and Means. With only 3 cosponsors and no companion Senate bill, passage probability is currently low, but the mechanism is structurally significant. The bill amends Section 1833(t)(16) of the Social Security Act to mandate separate Medicare Part B payment for 'specified cancer treatments' with a mean per day product cost exceeding a threshold ($350 in 2026). This prevents hospital outpatient departments from packaging high-cost oncology drugs into the standard bundled OPPS payment. Under current law, hospitals have a structural incentive to minimize the use of expensive branded drugs because they receive a fixed bundled payment — absorbing drug costs cuts into margin. The FAIC Act eliminates this disincentive by forcing separate, pass-through payment at ASP for qualifying cancer drugs, directly protecting $50B+ in oncology drug revenue at Merck, Bristol-Myers, Pfizer, Lilly, Amgen, and Johnson & Johnson. All six tickers trade at depressed levels relative to their 52-week ranges: MRK at $110.56 (down 8.09% in 30 days, 52-wk low $73.31, high $125.14), JNJ at $229.05 (down 6.3% in 30 days, 52-wk low $146.12, high $251.71), PFE at $26.70 (down 4.91% in 30 days, 52-wk low $21.97, high $28.75), BMY at $59.45 (down 1.98% in 30 days), AMGN at $346.98 (down 1.38% in 30 days), and LLY at $921 (flat 30 days). The 30-day selloff across these tickers — especially MRK (-8.09%) and JNJ (-6.3%) — reflects broader market concerns about drug pricing legislation and IRA Part D negotiation expansion, not cancer-specific payment policy. The FAIC bill, if it advances, provides a specific counter-catalyst for these depressed oncology-exposed names. The legislative path is long: the bill must pass through two House committees, the full House, then the Senate, and be signed into law. Authorization bills like this set policy but contain no direct funding. The mechanism is a statutory mandate on the Secretary of HHS, so passage would have immediate regulatory effect on Medicare payment policy. The early-stage status and lack of bipartisan Senate counterpart limit near-term market impact, but the bill is a clear signal of congressional intent to protect oncology drug manufacturers from hospital bundling pressure — a structural tailwind for the sector's largest revenue stream.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Some confirming evidence found across public data sources
What the bill does
The FAIC Act mandates separate Medicare Part B payment for qualifying cancer drugs (specified cancer treatments) with a mean per day product cost >= $350 (2026 threshold), preventing hospitals from packaging these drugs into bundled outpatient payments.
Who must act
Hospital outpatient departments (OPDs) receiving Medicare payment under the Hospital Outpatient Prospective Payment System (OPPS).
What happens
Hospitals lose their current ability to profit from the spread between bundled payment and the drug's acquisition cost; they must now administer qualifying branded cancer drugs and receive separate, pass-through payment at average sales price (ASP) plus a potential adjustment, removing the structural disincentive against using high-cost branded oncology therapies.
Stock impact
Merck's oncology portfolio includes Keytruda (pembrolizumab), which is among the highest-revenue cancer drugs globally. Separate payment eliminates the hospital incentive to substitute lower-cost alternatives or under-administer Keytruda. This directly protects Merck's ~$25B+ annual Keytruda revenue stream from hospital-driven formulary steering within the Medicare Part B outpatient setting.
What the bill does
The FAIC Act mandates separate Medicare Part B payment for qualifying cancer drugs with a mean per day product cost >= $350, preventing hospitals from bundling these drugs into outpatient payments.
Who must act
Hospital outpatient departments (OPDs) under Medicare OPPS.
What happens
Hospitals must receive separate, pass-through payment at ASP for qualifying cancer drugs, removing the financial incentive to avoid high-cost branded oncology therapies since the hospital no longer absorbs the drug cost within a bundled rate.
Stock impact
Bristol-Myers Squibb's oncology portfolio includes Opdivo (nivolumab) and Yervoy (ipilimumab) — both high-cost, high-margin immunotherapy products. The bill protects hospital willingness to administer these drugs, preventing potential revenue erosion from hospitals steering toward cheaper alternatives or biosimilars in the outpatient setting. Opdivo accounts for ~$8-9B in annual BMS revenue.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Protecting Americans from Unsafe Drugs Act of 2026
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Skinny Labels, Big Savings Act
ABC Safe Drug Act
American Innovation and R&D Competitiveness Act of 2025
DLA TROOP SUPPORT: $65.0M Department of Health and Human Services Contract
Most Favored Patient Act of 2026
Lowering Drug Costs for American Families Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →